Effect of capsaicin on the protozoan parasite Trypanosoma cruzi

FEMS Microbiol Lett. 2020 Dec 22;367(23):fnaa194. doi: 10.1093/femsle/fnaa194.

Abstract

Trypanosoma cruzi is the causative agent of Chagas disease. There are only two approved treatments, both of them unsuitable for the chronic phase, therefore the development of new drugs is a priority. Trypanosoma cruzi arginine kinase (TcAK) is a promising drug target since it is absent in humans and it is involved in cellular stress responses. In a previous study, possible TcAK inhibitors were identified through computer simulations resulting the best compounds capsaicin and cyanidin derivatives. Here, we evaluate the effect of capsaicin on TcAK activity and its trypanocidal effect. Although capsaicin produced a weak enzyme inhibition, it had a strong trypanocidal effect on epimastigotes and trypomastigotes (IC50 = 6.26 µM and 0.26 µM, respectively) being 20-fold more active on trypomastigotes than mammalian cells. Capsaicin was also active on the intracellular cycle reducing by half the burst of trypomastigotes at approximately 2 µM. Considering the difference between the concentrations at which parasite death and TcAK inhibition occur, other possible targets were predicted. Capsaicin is a selective trypanocidal agent active in nanomolar concentrations, with an IC50 57-fold lower than benznidazole, the drug currently used for treating Chagas disease.

Keywords: Trypanosoma cruzi; Chagas disease; arginine kinase; capsaicin; capsaicinoids; phenolic compounds.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arginine Kinase / metabolism*
  • Capsaicin / pharmacology*
  • Chagas Disease / drug therapy
  • Enzyme Activation / drug effects
  • Inhibitory Concentration 50
  • Nitroimidazoles / pharmacology
  • Trypanocidal Agents / pharmacology
  • Trypanosoma cruzi / drug effects*
  • Trypanosoma cruzi / enzymology

Substances

  • Nitroimidazoles
  • Trypanocidal Agents
  • Arginine Kinase
  • Capsaicin
  • benzonidazole